← Evidence map

ArticleLung Cancer (Auckland, N.Z.)2026

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges.

Kim Abbegail Tan Aldecoa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges. | OpenQuestion